We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award
News

Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award

Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award
News

Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Frost & Sullivan’s market research and analysis identified a critical need in lung cancer patient management for additional diagnostic information that enables better treatment decisions, particularly after initial therapy has failed. Frost & Sullivan analysts conclude that VeriStrat addresses this market need and state that “Biodesix’ VeriStrat test is changing the approach to the current paradigm of mutation-driven cancer diagnostics and measures instead an integrated effect of the host/tumor with respect to different drugs and drug combinations.” In the Best Practices report, analyst Winny Tan further notes that “Biodesix raises the bar in personalized medicine diagnostics by investing significantly in validation, clinical research and basic R&D. The company is a best-in-practice diagnostic test developer for an industry that lacks clinically validated biomarkers through a commitment to improving patient outcomes.”

“We are honored to receive this award from Frost & Sullivan,” commented David Brunel, Biodesix’ Chief Executive Officer. “We are proud that our hard work to bring products for personalized medicine to physicians and patients has been recognized.”

In evaluating companies for the award, Frost & Sullivan considered key industry challenges that should be addressed by a differentiated diagnostic test, and benchmarked Biodesix’ performance against competitors across five key metrics: Unique Features/Functionality; Quality/Complexity; Customization; Match to Target Market Needs; and Brand Perception of the Uniqueness of the Product. Biodesix was selected as the leader in the cancer diagnostics category after garnering top marks in the Frost & Sullivan customized Decision Support Matrix, an analytical tool that compares companies’ performance relative to each other with an integration of quantitative and qualitative.

Advertisement